Podcast: Biosimilar Development - - BioPharm International

ADVERTISEMENT

Podcast: Biosimilar Development


blog comments powered by Disqus


Anjan Selz, cofounder and CEO of Finox Biotech, takes us on the exciting journey from cell bank to Phase III, something that was achieved in just four years for his company’s biosimilar product, Afolia. In this first of three podcasts, Selz notes that Finox Biotech decided very early on that it wanted to move away from the “me too” approach to biosimilars and focus on product differentiation. Selz goes into detail about biosimilar candidate selection using Afolia (a follicle stimulating hormone), as an example, and describes the importance of having a good understanding of the patent landscape. Selz describes Finox’s outsourcing strategies in terms of partner selection—notably, all are based in Western Europe, and also offers insight into creating meaningful relationships in which success is a shared goal. Posted Dec. 2011.

ADVERTISEMENT

ADVERTISEMENT

Lundbeck CEO Resigns Due to Code of Conduct Breach
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Author Guidelines

Click here